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Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this
phase II study was to assess the efﬁcacy and toxicity of a dose-dense alternating chemotherapy regimen in this subset of
patients. High volume non-seminomatous germ-cell tumours was deﬁned as follows: at least two sites of non pulmonary
metastases, an extragonadal primary tumour, a serum human chorionic gonadotropin level higher than 10000 mIU ml
71,o ra
alpha-foetoprotein level higher than 2000 mIU ml
71. Patients who fulﬁlled these criteria were treated with the so-called BOP-
CISCA-POMB-ACE regimen (bleomycin, vincristine, and cisplatin; cisplatin, cyclophosphamide, and doxorubicin; cisplatin,
vincristine, methotrexate, and bleomycin; etoposide, dactinomycin, and cyclophosphamide) plus granulocyte colony-stimulating
factor. A total of 58 patients were enrolled. Patients were retrospectively classiﬁed according to the International Germ-Cell
Cancer Consensus Group classiﬁcation; 38 patients (66%) had poor-prognosis disease and 19 patients (33%) had
intermediate-prognosis. Patients received a median of 2.5 courses (range 0.25 to ﬁve courses) of the BOP-CISCA-POMB-ACE
regimen. Forty-two patients (72.4%) had a complete response to therapy. With a median follow-up time of 31 months, the 3-
year progression-free survival rate was 71% (95% conﬁdence interval, 60 to 84%) and the 3-year overall survival rate was 73%
(95% conﬁdence interval: 62 to 86%). The 3-year PFS rates were 83% (95% conﬁdence interval: 68 to 100%) in the
intermediate-prognosis group and 65% (95% conﬁdence interval: 51 to 82%) in the poor-prognosis group. Early side effects
included mainly grade 4 haematologic toxicity (neutropaenia in 79% of patients, thrombocytopaenia in 69%, anaemia in 22%),
grade 4 stomatitis (19%), and four early deaths (7% of patients), at least partially related to toxicity. The dose-dense BOP-
CISCA-POMB-ACE regimen is highly active in patients with non-seminomatous germ-cell tumours classiﬁed as intermediate-
prognosis or poor-prognosis according to the International Germ-Cell Cancer Consensus Group. Because outcomes with this
regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in
this subset of patients.
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The use of cisplatin-based chemotherapy and surgery in the ﬁrst-
line treatment of non-seminomatous germ-cell tumours (NSGCT)
has resulted in cure rates of approximately 80% during the past
two decades (Bosl and Motzer, 1997; Culine et al, 1996). Improved
treatment has led to the need to stratify patients by prognosis.
Although many groups have identiﬁed clinical and biological
features of NSGCT with prognostic relevance, there are consider-
able differences between the prognostic classiﬁcations that have
emerged from these analyses. These differences make it difﬁcult
to compare results of clinical trials. In 1997, the International
Germ-Cell Cancer Consensus Group (IGCCCG) published a
consensus prognostic index for NSGCT (International Germ-Cell
Cancer Consensus Classiﬁcation, 1997). This index stratiﬁes
patients into good-, intermediate-, and poor-prognosis subgroups
on the basis of three criteria: the primary tumour site, the levels
of serum tumour markers, and whether extra-pulmonary visceral
metastases are present. This index has been validated by the
IGCCCG and by other groups (Bower et al, 1997; Hinton et al,
2000). Patients allocated to the good-prognosis group have a high
probability of cure, but patients in the intermediate-prognosis and
poor-prognosis groups have 3-year survival rates of only 81% and
50%, respectively.
Since the recognition in the 1980s of a group of patients
with advanced NSGCT with a poor prognosis, a number of
attempts have been made to improve the cure rate in this
subgroup. In 1987, investigators from Indiana University
published a subgroup analysis of a randomised trial that
compared four cycles of cisplatin, bleomycin, and etoposide
(BEP) vs cisplatin, vinblastine, and bleomycin regimen (PVB).
The analysis showed that BEP produces better outcomes in
patients with poor-prognosis NSGCT, and the BEP became
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quent studies that have attempted to identify a regimen
superior to BEP in this setting have focused on increasing the
peak dose intensity (Ozols et al, 1988; Nichols et al, 1991; Fiza-
zi, 2002), using high-dose chemotherapy with autologous
haematopoietic stem cell support (Baume et al, 1990; Chevreau
et al, 1993), integrating ifosfamide into ﬁrst-line chemotherapy
(Nichols et al, 1998; de Wit et al, 1998), and developing
dose-dense alternating regimens (Kaye et al, 1998; Fizazi and
Zelek, 2000). So far, randomised trials have failed to identify
a regimen with efﬁcacy superior to that of BEP.
It has been suggested that increased dose intensity may lead to
improved results in germ-cell tumours (Samson et al, 1984; Boke-
meyer et al, 1999). However, on the basis of the results from two
randomised studies (Nichols et al, 1991; Chevreau et al, 1993) and
of our own trial comparing two doses of the CISCA/VB regimen
(Fizazi et al, 2002), we believe that increasing the peak doses is not
likely to improve cure. Indeed, this strategy results in a signiﬁcant
delay between courses of chemotherapy and limits the number of
potentially active agents that may be used to circumvent resistance
to therapy. Another way to increase dose intensity is to increase ‘dose
density’ – that is, to decrease the interval over which a speciﬁed dose
is given. This strategy has proven feasible and has now been used
worldwide in the treatment of a great variety of neoplasms (Fizazi
and Zelek, 2000). Taking advantage of the facts that several drugs
effective against NSGCT – including bleomycin, vincristine, cispla-
tin, and methotrexate – are not haematotoxic or are moderately
haematotoxic and that hematopoietic growth factors are available,
we designed a dose-dense multidrug regimen for high volume
NSGCT, called BOP-CISCA-POMB-ACE. This regimen is a hybrid
of three regimens previously shown to be individually effective
against NSGCT: BOP (bleomycin, vincristine, and cisplatin), which
was developed at the University of Colorado (Wettlaufer et al,
1984), CISCA (cisplatin, cyclophosphamide, and doxorubicin) which
was developed at The University of Texas M.D. Anderson Cancer
Center (Fizazi et al, 2002; Logothetis et al, 1985, 1986), and
POMB/ACE (cisplatin, vincristine, methotrexate, and bleomycin,
followed by etoposide, dactinomycin, and cyclophosphamide), which
has been used since 1979 at the Charing Cross Hospital, London
(Bower et al, 1997). Here we report the results of a phase II study
of this regimen.
PATIENTS AND METHODS
Eligibility
This was a prospective phase II trial. Signed informed consent
forms approved by the M. D. Anderson Cancer Center’s Institu-
tional Review Board were obtained from all patients before
enrolment. All patients had histologically conﬁrmed NSGCT,
evidence of dissemination, and a high disease volume according
to the modiﬁed M. D. Anderson classiﬁcation (Logothetis et al,
1986). High-volume NSGCT was deﬁned by the presence of at
least one of the following criteria: at least two sites of non-
pulmonary visceral metastases, an extragonadal primary tumour,
a serum human chorionic gonadotropin (hCG) level higher than
10000 mIU ml
71, or an alpha-foetoprotein (AFP) higher than
2000 mIU ml
71. Additional inclusion criteria included a white
blood cell count of at least 3000 mm
3, a platelets count of at
least 100000 mm
3, a creatinine clearance level of greater than
40 ml min
71, a bilirubin level less than 1.5 times the upper
limit of normal, and alanine transaminase level of no more than
four times the upper limit of normal. Excluded from this study
were patients infected by the human immunodeﬁciency virus
(they are the subject of a separate report (Fizazi et al, 2001))
and patients who had previously undergone chemotherapy. There
were no exclusion criteria based on performance status or life
expectancy.
Baseline assessment
Baseline assessment included a review of the histologic tumour type
and serum tumour marker assays for hCG, AFP, and lactate dehy-
drogenase (LDH). Radiographic studies at baseline included chest
radiography, and computed tomography (CT scan) of the pelvis,
abdomen and brain. A computed tomography of the chest was
performed in cases of suspicious thoracic lesions. A bone scan
was also performed when clinically indicated. A gallium scan of
the lung and a forced vital capacity measurement (FVC) were also
performed. Other baseline studies included a dental evaluation, an
audiogram, an electrocardiogram, an echocardiogram, a complete
blood count with platelet count, and an assessment of electrolytes,
testosterone level, and renal and liver function. Additional studies
were obtained as warranted by the patient’s clinical presentation.
Sonography of the contralateral testis was performed to detect
contralateral tumours.
Evaluation and supportive care during chemotherapy
A complete blood count with platelet count was obtained three
times a week. A physical examination and assessment of electro-
lytes, predicted creatinine clearance, and serum tumour markers
were performed before each course of chemotherapy. A FVC was
performed before each course that included bleomycin. If a drop
in the FVC of 10% or more below the baseline level was observed
and conﬁrmed, bleomycin was discontinued.
Patients were instructed to go to the hospital for a complete
blood count if they developed a fever. Broad-spectrum antibiotics
were started in the case of febrile neutropenia. Platelet transfusion
and red cell transfusion were also used in the case of severe throm-
bocytopenia (platelets level less than 10000 mm
3) and severe
anaemia (haemoglobin level less than 7 g dl
71). Intensive mouth
washes and acyclovir were used in the case of severe stomatitis.
Treatment
Induction chemotherapy consisted in the BOP-CISCA-POMB-ACE
regimen, the details of which are outlined in Table 1. Bleomycin
was given as a 24-h continuous infusion. Cisplatin was delivered
over a period of 2 h with simultaneous forced mannitol diuresis
as previously described (Hayes et al, 1977). Vincristine, etoposide
and dactinomycin were administered as an intravenous bolus.
Doxorubicin was given as a 48-h continuous infusion. Cyclopho-
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Table 1 BOP-CISCA-POMB-ACE regimen
Planned interval
between courses
Combination (days) Drug Dose
BOP 7 Bleomycin 30 U dl (CI)
Vincristine 2 mg dl
Cisplatin 100 mg m
72 d1
CISCA 14 Doxorubicin 35 mg m
72 d1,2 (CI)
Cyclophosphamide 400 mg m
72 d1,2
Cisplatin 100 mg m
72 d3
POMB 10 Vincristine 2 mg d1
Methotrexate 300 mg m
72 d1
Leucovorin 15 mg64d 2
Bleomycin 30 U d2,3 (CI)
Cisplatin 100 mg m
72 d4
ACE 14 Etoposide 100 mg m
72
d1,2,3,4,5
Actinomycin-D 0.5 mg d3,4,5
Cyclophosphamide 500 mg m
72 d1
CI: 24 h continuous infusion; d: day.
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was given as a 12-h continuous infusion and followed by leucovor-
in rescue. Leucovorin was given 24-h after the start of the
methotrexate infusion at a dose of 15 mg as an intravenous bolus
every 12 h for four courses. Granulocyte colony-stimulating factor
(G-CSF) was administered subcutaneously at a dose of
5 mg kg day
71 beginning the day after completion of chemother-
apy. G-CSF was continued for a minimum of 5 days and until
the absolute granulocyte count was higher than 1000 mm
3.
Chemotherapy was started 24 h after the discontinuation of G-
CSF and according to the schedule summarised in Table 1
provided that the absolute granulocyte count was higher than
1000 mm
3, the platelet count was higher than 50000 mm
3 (with-
out a decreasing trend), and any other grade 3 or 4 toxic effects
had resolved. The total number of chemotherapy courses was indi-
vidualised on the basis of tumour response. Patients received one
cycle of the BOP-CISCA-POMB-ACE regimen beyond the one in
which complete remission was achieved or in which a radiographi-
cally stable mass and normal levels of serum biomarkers were
established. In the case of a radiographically stable mass, explora-
tory surgery was performed to remove residual masses. Patients
who were found at surgery to have viable carcinoma received
two courses of salvage chemotherapy, typically cisplatin, ifosfamide,
and etoposide. Patients with brain metastases and remaining
masses after chemotherapy were treated with either neurosurgery
or radiotherapy; the choice of treatment was based upon the extent
of the disease and the patient’s underlying medical condition.
Assessment of response
Response was assessed after every complete cycle of BOP-CISCA-
POMB-ACE. Initially abnormal radiologic exams and serum tumour
markers were obtained. Patients in whom tumour markers normal-
ised and for whom there was no clinical or radiologic evidence of
disease were classiﬁed as having had a complete response to
chemotherapy (cCR). Patients with normal ﬁndings on tumour
marker studies and in whom completely resected residual masses
contained only necrosis or mature teratoma were classiﬁed as having
had a pathologic complete response (pCR). Patients with normal
tumour markers and in whom completely resected masses contained
viable cancer were classiﬁed as having had a surgical complete
response (sCR). Patients in whom tumour marker levels failed to
normalise, although a plateau was reached were classiﬁed as having
had an incomplete response (IR) and were proposed surgery or
salvage chemotherapy. All other responses were considered incom-
plete responses. Progressive disease (PD) was deﬁned as rising
tumour marker levels conﬁrmed at least twice or the appearance of
new lesions, except when pathologic evidence of a growing teratoma
syndrome (Logothetis et al, 1982; Andre ￿ et al, 2000) was provided.
Before response assessment, patients with tumour markers on plateau
were subjected to either surgical resection of residual masses or
follow-up of tumour markers. Patients who normalised tumour
markers after surgery were classiﬁed as either pCR or sCR according
to whether viable cancer was found at pathological examination.
Patients who were not submitted to surgerywere classiﬁed as progres-
sion in case of tumour marker raise after the plateau.
Statistical analysis
This phase II trial was conducted in two stages using the method of
Simon (Simon 1989) to determine whether the BOP-CISCA-
POMB-ACE regimen was likely to be of sufﬁcient efﬁcacy to be
worthy of further study. The main end-point of the trial was the
complete response rate. The following two hypotheses were consid-
ered: H0; P40.30, a complete response rate of no interest, vs H1;
P50.50, a complete response rate that would be of considerable
interest in further studies. The study plan was as follows: 22
patients would be entered in the ﬁrst stage of the study, and 24
would be entered in the second stage, for a total of 46 patients.
If the complete response rate was 32% (7 out of 22) or less at
the end of the ﬁrst stage, the study would be stopped. Otherwise,
accrual would continue. If the ﬁnal complete response rate was
37% (17 out of 46) or less, the regimen would not be studied
further. If the complete response rate was higher, the regimen
would be recommended for further study. If the true complete
response rate was 30%, the expected sample size for the trial would
be 30, and the probability of early termination would be 67%.
These calculations assumed type I and type II error rates of 10%
(i.e., there is 590% probability that the regimen would be recom-
mended for further study if the true efﬁcacy rate is 550% and
510% probability if the true efﬁcacy rate is 430%). After the
IGCCCG criteria were published in 1997 (3), it was decided to
expand the study to reduce the conﬁdence interval of the subgroup
of patients belonging to the poor-prognosis group according to the
IGCCCG.
Survival curves were generated by the method of Kaplan and
Meier. Overall survival (OS) was calculated from the date of enrol-
ment in the trial to the last date of follow-up. Progression-free
survival (PFS) was calculated from the date of inclusion into the
trial to the date of progression or relapse or to the date of last
follow-up. All analyses were performed using S-PLUS statistical
software.
RESULTS
Therapeutic outcome
Fifty-eight patients with high volume disseminated NSGCT were
enrolled in this trial between October 1993 and April 1998. All
patients were eligible and were included in the analysis. There were
57 males and one female. Patient characteristics are summarised in
Table 2. Patients were retrospectively classiﬁed according to the
IGCCCG classiﬁcation; 38 patients (66%) had poor-prognosis
disease and 19 patients (33%) had intermediate-prognosis disease.
Seventeen patients had an extragonadal primary tumour site.
Patients received a median of 2.5 courses of the BOP-CISCA-
POMB-ACE regimen (range 0.25 to 5 courses). Response to ther-
apy is summarised in Table 3. Response was assessed in an
intend to treat basis. Overall, 42 patients (72.4%) had a complete
response to therapy, including seven patients who had viable
non-teratomatous malignant cells in their resected residual masses.
Nine patients had an incomplete response including three who had
a partial response with serum tumour marker normalisation. Resi-
dual masses were not resected in these three patients because of
anatomic location of brain metastases (one patient), insufﬁcient
FVC to allow extensive thoracic surgery (one patient), and patient
refusal (one patient). Four patients (6.8%) were not assessable for
response because of early death.
After a median follow-up time of 31 months (range, 0.3 to 71
months), the 3-year PFS rate for the entire population was 71%
(95% conﬁdence interval [CI], 60 to 84%) and the 3-year OS rate
was 73% (95% CI, 62 to 86%). The 3-year PFS rates were 83%
(95% CI, 68 to 100%) in the intermediate-prognosis group and
65% (95% CI, 51 to 82%) in the poor-prognosis group. The 3-year
OS rates were 83% (95% CI, 67 to 100%) in the intermediate-
prognosis group and 67% (95% CI, 53 to 84%) in the poor-prog-
nosis group. Survival curves according to IGCCCG groups are
shown in Figure 1. The 3-year OS rate in patients with primary
mediastinal NSGCT was 64% (95% CI, 44 to 95%).
Toxicity and causes of death
Overall, the BOP-CISCA-POMB-ACE regimen was associated with
a high incidence of toxic effects. Table 4 summarises the distribu-
tion of grade 3 and 4 toxic effects. Haematologic and
gastrointestinal side effects (stomatitis and vomiting) were among
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were used. Peripheral neuropathy also occurred often (grade 1:
17%, grade 2: 19%, grade 3: 2%). Four patients died of toxicity-
related deaths. One patient died of a subarachnoid haemorrhage
secondary to thrombocytopaenia. Another patient, with a history
of polycystic bilateral kidney disease and a high-volume NSGCT
with bulky retroperitoneal nodes compressing the uretera and caus-
ing destruction of the lumbar vertebra, developed an acute renal
insufﬁciency and died of associated complications. Two patients
died of sepsis. Another patient developed acute leukaemia (refrac-
tory anaemia with excess blasts in transformation) 14 months after
a complete remission of NSGCT was documented. At the time of
this report, this patient is alive 2 years after treatment of his hema-
tologic malignancy. One patient died of pneumonia 3 years after
chemotherapy was completed and a complete remission of a
primary mediastinal NSGCT had been documented.
DISCUSSION
Patients with intermediate-prognosis and poor-prognosis NSGCT
according to the IGCCCG classiﬁcation have 3-year OS rates of
only 81 and 50%, respectively (International Germ-Cell Cancer
Consensus Classiﬁcation, 1997). The 3-year OS rates in our
prospective phase II study of the dose-dense BOP-CISCA-POMB-
ACE regimen (83 and 67% in the intermediate- and in the poor-
prognosis group, respectively) compare favourably with the
IGCCCG rates and also with those achieved with the BEP regimen
(Hinton et al, 2000; Kaye et al, 1998) although a direct comparison
is not possible since ours was not a randomised study.
In recent years, data have accumulated suggesting that a high
cure rate can be achieved in patients with intermediate- and
poor-prognosis NSGCT when dose-dense regimens are used
(Bower et al, 1997; Kaye et al, 1998; Fizazi and Zelek, 2000; Lewis
et al, 1991; Horwich et al, 1994, 1997; Harstrick et al, 1991; Germa
Lluch et al, 1992, 1999). However, among the studies that have
addressed this issue, only a few (Horwich et al, 1997) were
designed as ‘true’ formal phase II studies like the present study,
and only one was a randomised trial (Kaye 1998). One of the
oldest dose-dense schedules, the POMB/ACE regimen, consists of
a combination of seven drugs, recycled alternatively at 2-week
intervals. In patients with intermediate-prognosis and poor-prog-
nosis NSGCT according to the IGCCCG criteria, 3-year survival
with this regimen are 88 and 75%, respectively (Bower et al,
1997). Another accelerated induction regimen, the so-called C-
BOP-BEP regimen, has been developed at the Royal Marsden
Hospital in London (Horwich et al, 1994, 1997). This weekly regi-
men is a combination of cisplatin, bleomycin, vincristine,
etoposide, and carboplatin. Results are very promising: in 41
patients with poor-prognosis according to the IGCCCG criteria,
the 3-year OS rate was 91%. Surprisingly, results in intermediate-
risk patients were more disappointing, as the 3-year OS rate was
only 68% (Horwich et al, 1997). This regimen is now being eval-
uated in a phase II trial by the European Organization for
Research and Treatment of Cancer (EORTC). The German Coop-
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Table 3 Response
Response No. of patients (%)
Complete response to chemotherapy 2 (3)
Pathologic complete response 33 (57)
Surgical complete response 7 (12)
Incomplete response 9 (16)
Progressive disease 3 (5)
Not assessable 4 (7)
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Figure 1 Progression-free survival according to IGCCCCG groups.
Table 2 Patient characteristics
Characteristic No. of patients (n=58)
Median age (range), years 27.5 (14–45)
Performance status (ECOG)
02 2
12 5
29
31
41
Primary tumour site
Testis 40
Retroperitoneum 3
Mediastinum 14
Ovary 1
Prognostic group (IGCCCG)
Good 0
Intermediate 19
Poor 38
Non-evaluable (female patient) 1
Non-pulmonary visceral metastases
Liver 5
Brain 2
Bone 1
Spleen 1
Kidney 1
Tumour marker elevation
HCG450.000 UI l
71 15
AFP410.000 ng ml
71
LDH410 times upper limit of normal 1
Table 4 Severe treatment-related toxic effects
Toxic effect Grade 3 (%) Grade 4 (%)
Haematologic
Neutropenia 1 (2) 46 (79)
Anaemia 33 (57) 13 (22)
Thrombocytopenia 7 (12) 40 (69)
Stomatitis 14 (24) 11 (19)
Vomiting 7 (12) 3 (5)
Renal failure 2 (3) 0
Bilirubine increase 3 (5) 2 (3)
Hypomagnesaemia 6 (10) 1 (2)
Neurologic toxic effect 1 (2) 0
Skin reaction 1 (2) 0
Thrombophlebitis 1 (2) 0
Weight loss 4 (7) 0
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ence with a rapidly alternating combination. The 3-year OS rate
in 48 patients with poor-risk NSGCT according to this group’s
classiﬁcation was 76% (Harstrick et al, 1991). Similarly, investiga-
tors of the Spanish Germ-Cell Cancer Group have developed an
intensive alternating multidrug schedule, the so-called BOMP/EPI
regimen that produced a 64% 2-year OS rate in 38 patients with
poor-prognosis disease according to the IGCCCG criteria (Germa
Lluch et al, 1992, 1999). Finally the Medical Research Council
and the EORTC have reported the results of a phase III trial that
compared a rapidly recycled intensive regimen (BOP/VIP-B) to
the standard 4 BEP in 380 patients with poor-prognosis NSGCT
(Kaye et al, 1998). Unfortunately, the BOP/VIP-B regimen, which
was initially reported to be highly efﬁcient in 91 patients treated
in an uncontrolled study (Lewis et al, 1991) did not afford any
survival beneﬁt in this randomised study. Possible explanations
for these negative results are a higher number of toxicity-related
deaths (12 vs 4) and a higher proportion (10% vs 5%) of primary
mediastinal NSGCT, notorious for their poor outcome (Fizazi et al,
1998), in the intensive arm.
Although prophylactic G-CSF was used in our study, the toxicity
of the BOP-CISCA-POMB-ACE regimen was high, although
manageable in most cases. Four early deaths occurred that were,
at least in part, related to treatment toxicity. One patient developed
a secondary leukaemia, a phenomenon that has been extensively
described in germ-cell tumour survivors (Bokemeyer and Schmoll,
1995). Relatively high rates of toxicity-related death have previously
been reported in patients treated with dose-dense regimens (Bower
et al, 1997; Kaye et al, 1998; Lewis et al, 1991; Horwich et al, 1994,
1997; Harstrick et al, 1991; Germa Lluch et al, 1992, 1999). For
example, 6.5% and 7% patients died of toxicity after they had
received the BOP/VIP-B and the C-BOP-BEP regimens, respec-
tively (Kaye et al, 1998; Horwitch et al, 1997). However, it is
noteworthy that the toxicity-related death rate of patients with
poor-prognosis NSGCT treated with standard regimens is not
negligible. Indeed, although the toxicity-related death rate asso-
ciated with the standard BEP regimen is typically low (around
1%) in good-prognosis patients (Cvitkovic, 1998) this rate ranges
from 2% to 6.4% in poor-prognosis patients (Nichols et al,
1991; Kaye et al, 1998; Droz et al, 2001). There are at least two
possible ways to reduce the toxicity-related death rate associated
with dose-dense regimens in poor-prognosis patients in the future.
First, these regimens may be optimised with the goals of reducing
the incidence of profound grade 4 thrombocytopenia and neutro-
penia and of limiting the total dose of bleomycin, especially in
patients with multiple lung metastases (for example those with
the ‘choriocarcinoma syndrome’). Second, since about half of
patients with a poor-prognosis according to the IGCCCG are cured
with the BEP regimen, we need to improve the selection of patients
for potentially more active regimens so that patients who can be
cured with BEP are spared the added toxicity of these regimens.
Some authors have suggested that subgroups with different survival
rates can be identiﬁed in the poor-prognosis IGCCCG group (Koll-
mannsberger et al, 2000). Investigators from Memorial Sloan-
Kettering Cancer Center have suggested that tumour marker half-
life correlates with survival (Toner et al, 1990), although investiga-
tors from the Royal Marsden Hospital did not conﬁrm these
ﬁndings (Stevens et al, 1995). Whether a slow decrease in tumour
marker levels is a predictor of poor outcome in patients with poor-
prognosis or intermediate-prognosis NSGCT according to the
IGCCCG was very recently suggested (Mazumdar et al, 2001). This
subject is currently under study by a collaborative group involving
M. D. Anderson, the Institut Gustave Roussy, and the French Geni-
to-Urinary Cancer Group. Results are expected soon. If the
independent prognostic role of a rapid decrease in tumour marker
levels is established, this might provide a useful tool to better select
patients for dose-dense regimens in the future.
The results of the BOP-CISCA-POMB-ACE regimen appear very
promising in patients with poor-prognosis NSGCT according to
the IGCCCG. However, it is noteworthy that no signiﬁcant
progress has been documented in these patients in phase III trials
since 1987. Some investigators believe that a therapeutic plateau
has been reached (Nichols et al, 1998). Most phase III studies
performed in recent years have tested the addition of one concept
(e.g. increase in peak dose, use of high-dose chemotherapy plus
autologous haematopoietic stem cell support, or the addition of
a single new drug) to standard therapies. On the basis of the nega-
tive results of these studies, we hypothesise that signiﬁcant
advances may be achieved only by integrating several concepts in
a new strategy. This may be achieved by using dose-dense combi-
nations including new drugs that have been recently identiﬁed to
be active against NSGCT (e.g., paclitaxel, gemcitabine and oxalipla-
tin) and better identifying patients who are not likely to be cured
with the BEP regimen.
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